Cannabidiol Cancer Research Results

CBD, Cannabidiol: Click to Expand ⟱
Features:
Cannabidiol (CBD) is a cannabinoid compound found in cannabis plants.
Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from Cannabis sativa that has drawn interest for its potential anticancer properties.
Pathways:
-Mitochondrial dysfunction, with loss of membrane potential leading to the release of cytochrome c and activation of caspase cascades
-Receptor-Mediated Signaling (CB Receptors and Beyond)
-Can increase reactive oxygen species (ROS)
-Can induce ER stress, which activates the unfolded protein response.
-Suppress key survival and proliferation signaling cascades such as the PI3K/Akt/mTOR pathway.
-Impair angiogenesis

Cannabidiol — Cannabidiol (CBD) is a non-intoxicating phytocannabinoid from Cannabis sativa with pleiotropic signaling effects that include ion-channel modulation, lipid-membrane stress, mitochondrial injury, oxidative stress induction, and context-dependent receptor/transcriptional effects. It is formally classified as a plant-derived cannabinoid small molecule and, clinically, as the active ingredient of the FDA-approved oral drug Epidiolex for certain seizure disorders rather than for cancer treatment. Standard abbreviations include CBD; the major acidic biosynthetic precursor is CBDA. For oncology, the evidence base is still mainly preclinical, with recurrent themes of apoptosis or autophagic death, EMT and invasion suppression, and chemo-sensitization in selected models, but translation is constrained by formulation-dependent exposure, extensive first-pass metabolism, and clinically important drug-interaction and hepatic-safety considerations.

Primary mechanisms (ranked):

  1. Mitochondrial stress with ROS increase, membrane depolarization, and intrinsic cell-death signaling.
  2. TRP-channel mediated Ca²⁺ dysregulation, especially TRPV2 or TRPV4-linked stress responses in glioma models.
  3. ER stress and integrated stress-response signaling, including ATF4–DDIT3/CHOP-associated death programs.
  4. PI3K/Akt/mTOR survival-axis suppression with secondary effects on proliferation, autophagy, and metabolic fitness.
  5. Anti-migratory and anti-metastatic signaling, including EMT reversal and Wnt/β-catenin suppression in colorectal cancer models.
  6. PPARγ-associated pro-death and anti-proliferative signaling in some tumor contexts.
  7. Ceramide-linked stress signaling in pancreatic cancer models.
  8. Chemosensitization through enhanced drug uptake or stress amplification in selected models, especially glioma.

Bioavailability / PK relevance: CBD is highly lipophilic, has low and formulation-sensitive oral bioavailability, and undergoes extensive hepatic and gut metabolism primarily via CYP2C19, CYP3A4, and UGT pathways. Food markedly changes exposure; high-fat meals can increase systemic exposure several-fold. The approved prescription formulation has a long terminal half-life after repeated dosing, but oncology studies and commercial products are heterogeneous in formulation, route, and reliability of exposure.

In-vitro vs systemic exposure relevance: This is a major translation constraint. Many anticancer in-vitro studies use low-to-moderate or higher micromolar concentrations that may not be reproducibly achievable in tumors with standard oral dosing, especially with non-pharmaceutical products. Some local-delivery, inhaled, or nanoformulation approaches may improve relevance, but for most cancer contexts the mechanistic literature still outpaces clinically validated exposure-response data.

Clinical evidence status: Preclinical evidence is substantial. Human cancer evidence is limited to small early-phase studies, supportive-care trials, and ongoing exploratory cancer trials; there is no established cancer-directed indication. Current oncology guidance supports discussing cannabis or cannabinoids for selected supportive-care scenarios but recommends against using them as anticancer therapy outside clinical trials.

-Liver injury is one of the main labeled toxicities: ALT elevations above 3× ULN occurred in 12% to 13% of treated patients in controlled studies

Mechanistic ranking

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial ROS and membrane injury ROS ↑; ΔΨm ↓; cytochrome c release ↑; caspase signaling ↑ ↔ or less sensitive in some models R/G Apoptosis or lethal stress Most central cross-tumor mechanism; often upstream of apoptosis and stress-pathway collapse.
2 TRPV2 or TRPV4 Ca²⁺ influx Ca²⁺ influx ↑; stress signaling ↑; drug uptake ↑ Limited effect reported in some astrocyte comparisons P/R Autophagy, apoptosis, chemosensitization Especially relevant in glioma literature; supports both direct cytotoxicity and adjunct sensitization.
3 ER stress and integrated stress response ATF4 ↑; DDIT3 CHOP ↑; UPR stress ↑ Usually weaker or not well defined R/G Death-program engagement Frequently coupled to Ca²⁺ dysregulation, ceramide changes, and mitochondrial dysfunction.
4 PI3K Akt mTOR survival signaling PI3K/Akt/mTOR ↓ ↔ (context-dependent) R/G Reduced survival and growth A common convergence node rather than always the initiating lesion.
5 Apoptosis execution program Apoptosis ↑; caspase 3 8 9 ↑; PARP cleavage ↑ ↔ or less pronounced in selected comparisons G Tumor cell loss Robust downstream phenotype across many cell systems.
6 Autophagy and mitophagy Autophagy ↑; mitophagy arrest or lethal autophagy ↑ Unclear selectivity R/G Stress adaptation failure or non-apoptotic death Can be cytotoxic or partially adaptive depending on model; important in glioma work.
7 EMT and Wnt β-catenin axis Wnt/β-catenin ↓; Snail ↓; vimentin ↓; E-cadherin ↑; metastasis programs ↓ Not established as a core normal-cell effect G Migration and invasion suppression Strong recent relevance in colorectal cancer models and consistent with the Nestronics entry.
8 PPARγ signaling PPARγ ↑ ↔ (context-dependent) R/G Pro-apoptotic transcriptional shift Mechanistically meaningful but not universal across tumor types.
9 Mitochondrial ROS increase secondary redox axis ROS ↑ Potential antioxidant or mixed effects in non-cancer settings P/R Stress amplification Include as a secondary redox axis rather than as the sole mechanism because CBD redox effects are context-dependent.
10 HIF-1α and angiogenesis signaling HIF-1α ↓; pro-angiogenic tone ↓ Not clearly established clinically G Vascular support restraint Present in preclinical literature and also reflected on the Nestronics page, but not a top translation driver.
11 Ceramide stress signaling CerS1 ↑; ceramide stress ↑ Unknown R/G ER stress linked cytotoxicity Currently most notable in pancreatic cancer work; may be subtype-specific.
12 Glycolysis and lipogenesis Lipogenesis ↓; metabolic fitness ↓ Systemic lipid effects also occur outside oncology G Metabolic disadvantage Mechanistically relevant but less mature as a core anticancer axis than stress-death signaling.
13 Chemosensitization Sensitivity to cytotoxics ↑ Potential therapeutic window depends on regimen G Adjunct leverage Most persuasive in glioma and some combination-model systems; clinically still exploratory.
14 Clinical Translation Constraint Micromolar in-vitro activity often exceeds routine systemic tumor exposure Normal-tissue PK and DDI burden remain clinically relevant G Limits standalone translation Poor and meal-sensitive oral bioavailability, product heterogeneity, hepatic injury risk, sedation, and CYP UGT interactions are major constraints.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
Scientific Papers found: Click to Expand⟱
1103- CBD,    Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway
- vitro+vivo, NA, NA
Apoptosis↑, TumCP↓, TumCMig↓, TumMeta↓, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, Hif1a↓, Wnt/(β-catenin)↓, AXIN1↑, TumVol↓, TumW↓,
1199- CBD,    Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis
- in-vivo, Obesity, NA
lipoGen↓,
5812- CBD,    Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis
- Trial, Var, NA
other∅, OS∅, other∅,
5813- CBD,    Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis
- Review, Var, NA
Dose↝, BioAv↑, BioAv↓, BioAv↑,
5814- CBD,    Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline
- Review, Var, NA
eff↓,
5815- CBD,    Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents
- in-vitro, GBM, NA
TRPV2↑, selectivity↑, ChemoSen↑,
5816- CBD,    Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4
- in-vitro, GBM, NA
TRPV2↑, Ca+2↑, MitoP↑, eff↑,
5817- CBD,    COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
- vitro+vivo, Lung, A549
AntiTum⇅, tumCV↓, Apoptosis↑, eff↓, COX2↑, PPARγ↑,
5818- CBD,    Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress
- in-vivo, PC, PANC1
GRP78/BiP↑, ATF4↑, CHOP↑, UPR↑, TumCG↓, ER Stress↑, eff↓,
5819- CBD,    The potential role of cannabidiol (CBD) in lung cancer therapy: a systematic review of preclinical and clinical evidence
- Review, Lung, NA
Apoptosis↑, PPARγ↓, mtDam↑, ROS↑, EMT↓, CD8+↑, NK cell↑, ChemoSen↑, ATP↓, glucose↓, Ca+2↑, TRPV2↑,
5820- CBD,    Cannabidiol effects in stem cells: A systematic review
- Review, Var, NA
*other↑, CSCs↓, SOX2↓, other↝,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

glucose↓, 1,   lipoGen↓, 1,   PPARγ↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

Apoptosis↑, 3,  

Kinase & Signal Transduction ⓘ

TRPV2↑, 3,  

Transcription & Epigenetics ⓘ

other↝, 1,   other∅, 2,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

MitoP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

AXIN1↑, 1,   CSCs↓, 1,   EMT↓, 2,   SOX2↓, 1,   TumCG↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Ca+2↑, 2,   E-cadherin↑, 1,   N-cadherin↓, 1,   Snail↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,   Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↑, 1,   NK cell↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 2,   Dose↝, 1,   eff↓, 3,   eff↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

AntiTum⇅, 1,   OS∅, 1,   TumVol↓, 1,   TumW↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 47

Pathway results for Effect on Normal Cells:


Transcription & Epigenetics ⓘ

other↑, 1,  
Total Targets: 1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:54  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page